US drug approvals
39 approvals with a product on the US market
- Empagliflozin ANDA212330 · approved 22 Sep 2026
- Rivaroxaban ANDA218768 · approved 20 Feb 2026
- Lidocaine ANDA207059 · approved 9 Feb 2026
- Ticagrelor ANDA208537 · approved 28 Oct 2025
- Linagliptin ANDA208423 · approved 3 Sep 2024
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.